The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.

Slides:



Advertisements
Similar presentations
1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.
Advertisements

Correlation of Leukocyte Count with Clinical Outcomes in Hospitalized Patients with Community-Acquired Pneumonia: Results from Rapid Empiric Treatment.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Authors: Sujai M. Parker, Gunjan N. Jodi, Jalak Jani
Hepatitis web study H EPATITIS W EB S TUDY H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School.
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
ADAP ADVOCACY ASSOCIATION 2013 HIV/HCV CO-INFECTION ADAP SUMMIT ROBERT L. CALDWELL, PH.D. A MEDICAL PERSPECTIVE ON HIV/HCV CO- INFECTION HIV and Hepatitis.
Treatment Evaluation of HTLV infection treatment of asymptomatic HTLV carriers is not indicated.
Washington D.C., USA, July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,
Surveillance of hepatitis C Infection in France JC Desenclos, Département des Maladies Infectieuses Institut de Veille Sanitaire.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,
Renal Transplantation for HIV/HCV Co-infected Patients Solid Organ Transplantation and People With HIV: Ethics and Policy Conference David Oldach & Robert.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Estimating the Burden of Serious Fungal Diseases in Thailand Methee Chayakulkeeree 1, David W. Denning 2* 1 Division of Infectious Diseases and Tropical.
Mortality Differences among Hospitalized Patients with Severe Community-acquired Pneumonia in Three World Regions: Results from the Community-Acquired.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.
HIV Disease and Hepatitis C Virus (HCV) Co-Infection – Florida, 2011 HIV/AIDS & Hepatitis Program - Surveillance Section HIV Disease data from 1981 through.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
Pennsylvania: The State of HCV 2015
POPULATION PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN HCV/HIV OR HBV/HIV CO-INFECTED INDIVIDUALS J.P. Cruz 1,2, D. Matias 1, C. Carvalho 1, J. Morais.
Module 4: Testing and monitoring. Module 5: Testing and monitoring Module goal To introduce participants to best practice regarding the different tests,
Positive impact of HCV treatment initiation on adherence to HIV treatment in co-infected patients: implications for access to HCV care Roux P 1, Fugon.
HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients Roger Bedimo, MD; Henning Drechsler, MD; Song Zhang, PhD;
Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.
HIV Surveillance in Women National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
Slideset on: Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the.
The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.
Date of download: 6/21/2016 From: HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease: A Cohort Study Ann Intern Med. 2013;158(9):
Identification of Potential Risk Factors for Mother-to- Infant HCV Transmission Slideset on: Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
QUALI DIFFERENZE IN RAPPORTO AL SESSO NELLA COINFEZIONE HCV/HIV? I DATI ITALIANI DALLA COORTE ICONA Antonella Cingolani Clinica Malattie Infettive, UCSC,
Provider Initiated HIV Counseling and Testing Unit 1: Introduction to HIV/AIDS.
Printed by The use of HARRT has significantly decreased the deaths among HIV-infected patients, there has been a shift from AIDs-defining.
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Henry Masur, MD Bethesda, Maryland
Introduction Data Statistical Methods Table 1: Prevalence of Prior Hip Fracture and Incidence of New Hip Fractures and Fractures of Any Type.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Kris V. Kowdley, Patricia Belt, Laura A. Wilson, Matthew M. Yeh, Brent A. Neuschwander-Tetri, Naga Chalasani, Arun J. Sanyal, and James E. Nelson ; for.
Treatment of HBV/HCV Coinfection
Hepatitis C.
Abstract MOAB0301 Hepatitis C Care Cascade for People Living With HIV in the Country of Georgia Nikoloz Chkhartishvili1, A. Abutidze1, N. Bolokadze1, O.
No conflict of interest
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.
Prevalence of Hepatitis C Virus Genotypes in Bangladesh
Vrushali Patwardhan, Dinesh Kumar, Varun Goel, Sarman Singh
A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova
hospitalized with spontaneous bacterial peritonitis
DOES HIV/ HEPATITIS COINFECTION AFFECT PEOPLE ACCESSING CARE FOR HIV
Underwriting Screening Liver Test Abnormalities:
Outline.
The Aging Liver in the Aging HIV and HCV Patients
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Evaluation of the Patient With HCV Infection
Impact of Hepatitis C, HIV, or Both on Survival in Veterans in Care Before and After the Introduction of HAART (1996) SL Fultz, MD, MPH CH Chang, PhD AA.
VACS Scientific Meeting October 15, 2008 Joseph K. Lim, M.D.
Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu Sriram Maringanti 2, Amy Wilson 2, Martin Gnoni 2, Timothy Wiemken 2, Shirish Barve 1, Craig McClain 1, Paula Peyrani Division Gastroenterology and Hepatology and Nutrition, 2. Division of Infectious Diseases, University of Louisville. Louisville, KY ABSTRACT Background: At present, an estimated 40 million people are infected with HIV worldwide, and 180 million are HCV-infected. A third of HIV-infected individuals in Europe and the USA have HCV co-infection. As a result, HCV is now regarded as an opportunistic infection in people with HIV infection. HCV infection has been reported as the most common cause of death in HIV infected subjects which may be due to systemic inflammation enhancing HIV replication and CD4 cell depletion. The objective of our study was to define the severity of liver fibrosis in patients with HCV-HIV confection and evaluate if an association exists between the severities of HCV induced liver fibrosis and CD4+ cell count. Methods Age (year) X AST / Retrospectively, the study enrolled 145 female with HIV disease on care at the University of Louisville Wings Clinic, Of these a group of only 20 Patients were HCV positive. Liver fibrosis was defined using the Fib-4 score. The Fib-4 score was calculated as = Age (year) X AST / Platelet Count X ALT ½ Platelet Count X ALT ½. The severity of HIV infection was defined by the CD4+ cell count. A simple linear model was used to correlate Fib-4 with CD4+ cell count. Results The correlation between liver fibrosis and CD4+ cell count is depicted in the following figure. The linear model results are as follows: y= This indicates that for every 1 point increase in Fib-4, the CD4+ cell count decreases by 70 cells. Conclusions This study demonstrates that as the liver fibrosis increases, the CD4+ cell count of the patient deteriorates. HCV/HIV co- infection affects the immunocompetence of the patients. Also the systemic inflammatory response associated with increased liver fibrosis may acts as cofactor for HIV disease progression. Further studies confirming the role of systemic inflammatory responses induced by HCV as a cofactor for HIV disease progression may lead to the development of therapeutic strategies INTRODUCTION REFERENCES RESULTS (Cont’d)  The study demonstrates an inverse correlation between liver fibrosis and CD-4 cell count, for every 1 point increase in Fib-4, the CD4+ cell count decreases by 70 cells.  Future research should focus on the influence of HCV on natural history of HIV disease and the management of HCV co-infected patients for better clinical outcomes. Physicians should have a high suspicion of HCV co-infection in HIV patients because of increasing prevalence CONCLUSIONS Figure 1: shows the association between the absolute CD4+ cell count and the liver fibrosis score (FIB-4). Study design and study population:  Wings Clinic Women’s Cohort study is a retrospective observational study of HIV-infected female patients managed at the Wings Clinic in Louisville, KY from 2006 to Based on the results, patients were divided into two groups: those with HIV mono-infection and those with HIV/HCV co- infection.  We retrospectively studied the medical charts of the patients and collected data from for  HCV co-infection is common in human immunodeficiency virus seropositive patients due to shared route of viral transmission. Liver disease is currently the leading cause of non-AIDS related death among HCV/HIV co-infected patients.  There is clear cut evidence that HIV impacts HCV[5] but the impact of HCV co-infection on HIV is controversial.  The objective of this study was to examine the impact of HCV co-infection on HIV disease progression and to evaluate the association between indirect marker for the fibrosis and the severity of HIV disease. MATERIALS AND METHODS Statistical Analysis:  HIV disease progression was evaluated using CD4+ cell count  The assessment of the liver fibrosis is calculated using the Fib-4.  A simple linear model was used to correlate the fibrosis as Fib-4 with CD4+ cell count. A total of 20 female HIV-HCV patients were studied from Wings Clinic Cohort Study.  Patient characteristics are shown in table 1.  Table 2 shows the risk factors for Hepatitis C patients.  Figure 1 shows the association between the absolute CD4+ cell count and the liver fibrosis score. The linear model results are as follows: y= This indicates that for every 1 point increase in Fib-4, the CD4+ cell count decreases by 70 cells. 1.Expanded HIV testing and trends in diagnoses of HIV infection - District of Columbia, Risk factorsHCV patientsPercentage Heterosexual20100 Intravenous drug use325 Homosexual00 Transfusion related00 Table 2 Risk factors for Hepatitis C. Table 1.Patient characteristics. Patient CharacteristicNumberPercentage Age < > AST < ALT < Platelet < Fib-4 score < CD4 count < Study Definitions:  To classify patients into HIV/HCV co-infection group, we included patients with documented evidence of positive serology for HCV antibody and/or positive PCR for HCV RNA.  The Fib-4 indirect invasive marker of liver fibrosis was used for analysis. This measure can be calculated using readily available patient and laboratory data. Fib-4 Fib-4  Age (years)  AST is Aspartate amino transferase.  ALT is Alanine amino transferase.  Platelet count (10/ L)  The severity of HIV infection was defined by the CD4+ cell count.  Data on current alcohol usage, smoking and HIP-B infection was derived from patient’s charts. RESULTS RESULTS (Cont’d) Habits Alcohol < 2 drinks/week 2 10 Tobacco6 30 HIP B0 0 Table 3 Risk factors for liver fibrosis.